Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma
JAMA Network Open · 23.01.2024 · 7 (1) · e2352830
DOI: 10.1001/jamanetworkopen.2023.52830 ↗Kurz gefasst
Kontrollierte klinische Studie in der Zeitschrift JAMA Network Open, online erschienen am 23.01.2024. Verfasst von Peter Thuss-Patience und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Cancer Immunology, Charité-University Medicine Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Monoclonal, Humanized, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Adding immune checkpoint inhibitors to chemotherapy has been associated with improved outcomes in metastatic esophagogastric adenocarcinoma, but treatment combinations and optimal patient selection need to be established.
Objective
To investigate the efficacy and tolerability of the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab. Design, Setting, and Participants This multicenter, single-group, phase 2 nonrandomized controlled trial was conducted among patients with second-line metastatic esophagogastric adenocarcinoma. Patients pretreated with platinum plus fluoropyrimidine between April 2019 and November 2020 across 10 German centers (median follow-up, 27.4 months [95% CI 22.0-32.9 months]) were included. Data analysis was performed from January to December 2022.
Interventions
Patients received ramucirumab at 8 mg/kg on days 1 and 15, avelumab at 10 mg/kg on days 1 and 15, and paclitaxel at 80 mg/m 2 on days 1, 8, and 15 every 4 weeks. Main Outcomes and Measures The prespecified primary end point was overall survival (OS) rate at 6 months, with the experimental therapy considered insufficiently active with an OS rate of 50% or less and a promising candidate with an OS rate of 65% or greater.
Results
Of 60 enrolled patients, 59 patients (median [range] age, 64 [18-81] years; 47 males [70.7%]) were evaluable, including 30 patients with metastatic adenocarcinoma of the stomach and 29 patients with gastroesophageal junction. All patients were pretreated with platinum plus fluoropyrimidine, and 40 patients (67.8%) had received prior taxanes; 24 of 56 evaluable patients (42.9%) had a PDL-1 combined positive score (CPS) of 5 or greater, centrally assessed. The OS rate at 6 months was 71.2% (95% CI, 61.5%-83.7%). The median OS in the intention-to-treat population (59 patients) was 10.6 months (95% CI, 8.4-12.8 months) overall. Among patients assessable by central pathology, median OS was 9.4 months (95% CI, 7.2-11.7 months) in 32 patients with a PDL-1 CPS less than 5 and 14.0 months (95% CI, 6.0-22.1 months) in 24 patients with a PDL-1 CPS of 5 or greater ( P = .25). Treatment was generally well tolerated, without unexpected toxicities. Patients with higher vs lower than median T cell repertoire richness showed an increased median OS of 20.4 months (95% CI, 7.7-33.0 months) compared with 8.3 months (95% CI, 3.7-12.9 months; hazard ratio, 0.43; 95% CI, 0.23-0.81; P = .008). Patients with lower vs higher than median cell-free DNA burden had a median OS of 19.2 months (95% CI, 8.9-29.6 months) compared with 7.3 months (95% CI, 3.2-11.4 months; hazard ratio, 0.30; 95% CI, 0.16-0.59; P < .001). Conclusions and relevance In this study, the combination of avelumab with paclitaxel plus ramucirumab showed favorable efficacy and tolerability in the second-line treatment for metastatic esophagogastric adenocarcinoma. A PDL-1 CPS score of 5 or greater, cell-free DNA level less than the median, and T cell repertoire richness greater than the median were associated with increased median OS. Trial Registration ClinicalTrials.gov Identifier: NCT03966118
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Cancer Immunology, Charité-University Medicine Berlin, Berlin, Germany.
- Hematology-Oncology Practice Eppendorf, Hamburg, Germany.
- University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Medical Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.
- Hematology-Oncology Practice Medizinisches Versorgungszentrum Mitte, Leipzig, Germany.
- Institute of Clinical Cancer Research at Krankenhaus Nordwest, University Cancer Center, Frankfurt, Germany.
Zitieren
APA
Thuss-Patience, P., Högner, A., Goekkurt, E., Stahl, M., Kretzschmar, A., Götze, T., Stocker, G., Reichardt, P., Kullmann, F., Pink, D., Bartels, P., Jarosch, A., Hinke, A., Schultheiß, C., Paschold, L., Stein, A., & Binder, M. (2024). Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma. JAMA Network Open, 7(1), e2352830. https://doi.org/10.1001/jamanetworkopen.2023.52830
Vancouver
Thuss-Patience P, Högner A, Goekkurt E, Stahl M, Kretzschmar A, Götze T, et al. Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma. JAMA Network Open. 2024;7(1):e2352830. doi:10.1001/jamanetworkopen.2023.52830
BibTeX
@article{ThussPatience2024,
author = {Thuss-Patience, Peter and Högner, Anica and Goekkurt, Eray and Stahl, Michael and Kretzschmar, Albrecht and Götze, Thorsten and Stocker, Gertraud and Reichardt, Peter and Kullmann, Frank and Pink, Daniel and Bartels, Prisca and Jarosch, Armin and Hinke, Axel and Schultheiß, Christoph and Paschold, Lisa and Stein, Alexander and Binder, Mascha},
title = {Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {1},
pages = {e2352830},
doi = {10.1001/jamanetworkopen.2023.52830}
}
EUVIMED